8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 6, 2004

MILLIPORE CORPORATION

(Exact name of registrant as specified in its charter)

MASSACHUSETTS	001-09781 (0-1052)	04-2170233
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

290 Concord Road, Billerica, Massachusetts 01821

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone number, including area code: (978) 715-4321

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5. 02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Francis J. Lunger will step down from his position as President and CEO of Millipore Corporation effective January 1, 2005. Mr. Lunger will also step down as a Director and as Chairman of the Board of Directors of the Company on March 1, 2005.

Item 8.01 Other Events

On December 6, 2004, Millipore Corporation issued a press release announcing that Dr. Martin D. Madaus will be joining the Company as President and CEO on January 1, 2005 and will be joining the Company’s Board of Directors on the same day. The press release also announced that Francis J. Lunger, Millipore’s outgoing President and CEO, will remain as Chairman of the Board of the Company until March 1, 2005. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit Number	Title
99.1	Press Release issued December 6, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MILLIPORE CORPORATION

/s/ Jeffrey Rudin

Jeffrey Rudin

Vice President and General Counsel

Date: December 6, 2004

-3-

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued December 6, 2004

-4-

EX-99.1

Exhibit 99.1

Investor Contact: Geoffrey Helliwell Treasurer 978-715-1041 800-225-3384 Geoffrey_Helliwell@Millipore.com Media Contact: Thomas Anderson Vice President Corporate Communications 978-715-1043 800-225-3384 Thomas_Anderson@Millipore.com

New President and CEO of Millipore Effective January 1, 2005

Billerica, Massachusetts, December 6, 2004—Millipore Corporation (NYSE: MIL) announced that its new President and CEO, Martin D. Madaus, will start on January 1, 2005. Dr. Madaus will also join Millipore’s Board of Directors on January 1. Dr. Madaus will assume the role of President and CEO from Francis J. Lunger, who will remain as Chairman of the Board until March 1, 2005.

Dr. Madaus comes to Millipore from Roche Diagnostics Corporation where he led a $1.9 billion business with 4,000 employees. His appointment to Millipore was announced on October 25, 2004.

About Millipore

Millipore is a multinational, high technology bioscience company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the worldwide life science research, biotechnology and pharmaceutical industries. For more information, visit www.millipore.com.

Millipore Forward Looking Statement Disclaimer

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore’s future

operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics and their ultimate commercial success; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore’s filings with the SEC.